Back to News
Market Impact: 0.48
Viking Therapeutics' obesity drug shows 22% weight loss in study
Source: reuters.com
Healthcare & BiotechProduct Launches
Viking Therapeutics reported that its experimental weekly GLP-1 obesity drug produced 22% average body-weight loss after 33 weeks in a maintenance study. The result is a strong clinical efficacy signal for Viking's obesity pipeline and could strengthen its competitive position in the high-growth GLP-1 market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
VKTX0.85
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Musk says Tesla to wind down polarising Cybertruck production as sales lag
- Tesla to wind down Cybertruck production at Texas factory next year to make room for Cybercab
- Ferrari’s Luce was ridiculed as a ‘Magic Mouse on wheels.’ Now the EV is sold out for 2027, and buyers haven’t even driven it yet
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs